Japan Tissue Engineering Co., Ltd. Announces Non-Consolidated Earnings Results for Third Quarter Ended Sept. 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2017
January 30, 2017 at 09:00 pm IST
Share
Japan Tissue Engineering Co., Ltd. announced non-consolidated earnings results for third quarter ended Sept. 30, 2016. For the quarter, the company reported net sales of ¥1,154 million, operating loss of ¥198 million, ordinary loss of ¥200 million, net loss of ¥203 million or ¥5.02 diluted per share, loss before income taxes of ¥200.8 million compared to the net sales of ¥956 million, operating loss of ¥605 million, ordinary loss of ¥594 million, net loss of ¥597 million or ¥14.72 diluted per share, loss before income taxes of ¥594.5 million for the same quarter a year ago.
For the year ending March 31, 2017, the company forecasted net sales of ¥2,098 million, operating income of ¥11 million, ordinary income of ¥10 million, net income of ¥5 million or ¥0.14 diluted per share.
Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.
Japan Tissue Engineering Co., Ltd. Announces Non-Consolidated Earnings Results for Third Quarter Ended Sept. 30, 2016; Provides Earnings Guidance for the Year Ending March 31, 2017